Stoke and Biogen Showcase Long-Term Data for Dravet Syndrome Treatment Zorevunersen — Biogen Inc.

Event summary

Stoke Therapeutics and Biogen presented 4-year clinical data for zorevunersen at the 16th European Epilepsy Congress, showing sustained improvements in cognition, behavior, and seizure reduction in Dravet syndrome patients.
The Phase 3 EMPEROR study results are expected in Q3 2027.
Zorevunersen demonstrated potential disease-modifying effects, including reductions in severe seizure types and improvements in quality of life.
77% of patients from the Phase 1/2a studies continued into open-label extensions, with the treatment being generally well-tolerated.

The big picture

The presentation of long-term data for zorevunersen underscores the potential of RNA medicine in treating rare neurological diseases. Biogen's collaboration with Stoke Therapeutics highlights the strategic importance of targeting Dravet syndrome, a condition with no approved disease-modifying therapies. The upcoming Phase 3 results will be critical in determining the commercial viability of zorevunersen in a competitive rare disease market.

What we're watching

Regulatory Approval: The pace at which zorevunersen secures regulatory approvals following the Phase 3 results in 2027.
Commercialization Strategy: How Biogen and Stoke Therapeutics plan to commercialize zorevunersen, given their global rights split.
Long-Term Efficacy: Whether the sustained improvements in cognition and behavior observed in the 4-year data will translate into long-term disease modification.